Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas' Disease

Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0153521. doi: 10.1128/AAC.01535-21. Epub 2021 Oct 4.


Phenotypic screening identified an arylsulfonamide compound with activity against Trypanosoma cruzi, the causative agent of Chagas' disease. Comprehensive mode of action studies revealed that this compound primarily targets the T. cruzi proteasome, binding at the interface between β4 and β5 subunits that catalyze chymotrypsin-like activity. A mutation in the β5 subunit of the proteasome was associated with resistance to compound 1, while overexpression of this mutated subunit also reduced susceptibility to compound 1. Further genetically engineered and in vitro-selected clones resistant to proteasome inhibitors known to bind at the β4/β5 interface were cross-resistant to compound 1. Ubiquitinated proteins were additionally found to accumulate in compound 1-treated epimastigotes. Finally, thermal proteome profiling identified malic enzyme as a secondary target of compound 1, although malic enzyme inhibition was not found to drive potency. These studies identify a novel pharmacophore capable of inhibiting the T. cruzi proteasome that may be exploitable for anti-chagasic drug discovery.

Keywords: Chagas’ disease; drug discovery; drug target; malic enzyme; mechanism of action; proteasome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chagas Disease* / drug therapy
  • Drug Discovery
  • Humans
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors / pharmacology
  • Trypanosoma cruzi* / chemistry


  • Proteasome Inhibitors
  • Proteasome Endopeptidase Complex